DBV Technologies S.A.
DBV Technologies S.A.（DBVT）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · DBVT · 截至 2025年3月31日
股东结构概览
17
机构持有人数
▼ 1 vs Q4
$16.83M
机构持仓总市值
▲ $8.37M vs Q4
23.92M
总流通股
freeFloat 60.78%
2.47M
13F 申报持股数
▼ 269,123 vs Q4
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
DBVT 最大股东 · 机构持仓
Q1 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 1.46M | 1.42% | 1.42% | $9.97B | May 15, 2025 | — held |
YIHENG CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 656.3K | 63.96% | 63.96% | $4.48B | May 16, 2025 | — held |
UBS GROUP AG biological products, (no diagnostic substances) | 163.5K | 15.93% | 15.93% | $1.11B | May 13, 2025 | ▲ 1.1K |
CANTOR FITZGERALD, L. P. biological products, (no diagnostic substances) | 95.5K | 9.30% | 9.30% | $651.04M | May 15, 2025 | NEW |
MORGAN STANLEY biological products, (no diagnostic substances) | 40.3K | 3.92% | 3.92% | $274.65M | May 15, 2025 | ▼ 5.5K |
NAN FUNG GROUP HOLDINGS LTD biological products, (no diagnostic substances) | 37.1K | 3.61% | 3.61% | $252.99M | May 14, 2025 | — held |
OPTIVER HOLDING B.V. biological products, (no diagnostic substances) | 8.3K | 0.81% | 0.81% | $56.93M | May 15, 2025 | ▲ 8.3K |
RHUMBLINE ADVISERS biological products, (no diagnostic substances) | 3.9K | 0.38% | 0.38% | $26.53M | May 29, 2025 | ▲ 991 |
FEDERATION DES CAISSES DESJARDINS DU QUEBEC biological products, (no diagnostic substances) | 425 | 0.04% | 0.04% | $2.90M | May 15, 2025 | — held |
TORONTO DOMINION BANK biological products, (no diagnostic substances) | 320 | 0.03% | 0.03% | $2.18M | May 15, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q1 2025 对比上季度
Q1 2025
4
增持
+10.5K 股4
新建仓
首次建仓2
减持
−5.5K 股5
清仓
完全退出净股数变化（前50家）
+5.0K
+10.5K / −5.5K
净新增持仓人
+1
新建 4 个 / 退出 5 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
DBVT 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
2
买入笔数
1
卖出笔数
2.00
买卖比
$25M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Mohideen Pharis Chief Medical Officer | Jan 29, 2026 | Sale | 534 | $4.86 | $2.6K | 145.0K | Form 4 ↗ |
EPIC Bpifrance Member of 10% owner group | Dec 17, 2025 | Sale | 2,036,990 | $4.84 | $9.86M | 8.64M | Form 4 ↗ |
EPIC Bpifrance Member of 10% owner group | Dec 17, 2025 | Sale | 40,000 | $5.28 | $211.2K | 8.60M | Form 4 ↗ |
EPIC Bpifrance Member of 10% owner group | Dec 18, 2025 | Sale | 1,292,103 | $4.19 | $5.41M | 7.30M | Form 4 ↗ |
Mohideen Pharis Chief Medical Officer | Nov 21, 2025 | Award | 253,000 | $2.90 | $733.7K | 253.0K | Form 4 ↗ |
Mohideen Pharis Chief Medical Officer | Nov 21, 2025 | Award | 44,000 | — | — | 145.5K | Form 4 ↗ |
Mohideen Pharis Chief Medical Officer | Nov 20, 2025 | Sale | 6,496 | $2.88 | $18.7K | 103.2K | Form 4 ↗ |
Mohideen Pharis Chief Medical Officer | Nov 21, 2025 | Sale | 1,624 | $2.77 | $4.5K | 101.5K | Form 4 ↗ |
Boucinha Virginie Chief Financial Officer | Nov 21, 2025 | Award | 192,000 | $2.90 | $556.8K | 192.0K | Form 4 ↗ |
Boucinha Virginie Chief Financial Officer | Nov 21, 2025 | Award | 32,000 | — | — | 70.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
DBV Technologies S.A.（DBVT）主要由机构投资者持有，机构持股比例约为 10.3%。公司内部人员持股约 39.22%，散户及公众持股约占剩余的 50.46%。
DBV Technologies S.A. 最大机构股东为 BAKER BROS. ADVISORS LP，截至 March 31, 2025 持有约 1.46 million 股，占总流通股的 1.42%。
目前共有 17 家机构持有 DBVT 股票，合计持仓市值约 $16,831,526，数据来源为最新 SEC 13F 申报。
常见问题
DBVT ownershipDBV Technologies S.A.（DBVT）主要由机构投资者持有，机构持股约 10.3%。最大股东为 BAKER BROS. ADVISORS LP，持股比例 1.42%。内部人员持股约 39.22%。数据来源 SEC Form 13F，截至 March 31, 2025。